Cellnovo said now that its first large-scale production line - located at Flex’s facility in Austria - has reached capacity, it is looking to increase production and lower costs.
“We are building a second production line to increase the total production capacity of our insulin cartridge,” Cellnovo spokesperson Nicolas Merigeau told us.
“One of our goals has been to reduce the cost of production of our insulin cartridges, which is the consumable part of the Cellnovo Diabetes Management System. The location decision for this new production line allows us to benefit from cost efficiencies by significantly reducing the overall cost of goods sold,” he said.
Similarly to the Austrian line, the Romanian facility has a production capacity of 600,000 cartridges per year. The second line is expected to reach capacity in H1 2018.
Diabetes management
Cellnovo’s insulin pump includes a mobile touchscreen controller and a blood-glucose reader. The device transmits data automatically, which enables the patient’s condition to be monitored by health care professionals and family members in real-time.
Merigeau said the second production line will meet an increased demand for Cellnovo’s diabetes management technology.
“All our clients will benefit from this second line; our objective is to increase production capacity to meet the already existing demand for our unique micro-pump for insulin delivery,” he said.
Cellnovo is not disclosing whether the increased production would create jobs.